Page last updated: 2024-11-08

alanine and Bilateral Headache

alanine has been researched along with Bilateral Headache in 3 studies

Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.

Research Excerpts

Excerpt	Relevance	Reference
"To characterize clinical features of a very large pedigree with early-onset Alzheimer disease (AD) in which all affected individuals carry the identical glutamic acid-to-alanine mutation at codon 280 in the presenilin-1 gene."	3.69	Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. ( Arango-Lasprilla, JC; Arango-Viana, JC; Arcos-Burgos, M; Ardilla, A; Behrens, IM; Goate, AM; Hincapíe, L; Kosik, KS; Lemere, CA; Lendon, C; Lopera, F; Madrigal, L; Martínez, A; Norton, J; Ossa, JE; Rosselli, M; Ruiz-Linares, A, 1997)

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (33.33)	18.7374
1990's	1 (33.33)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Sax, PE	1
Wohl, D	1
Yin, MT	1
Post, F	1
DeJesus, E	1
Saag, M	1
Pozniak, A	1
Thompson, M	1
Podzamczer, D	1
Molina, JM	1
Oka, S	1
Koenig, E	1
Trottier, B	1
Andrade-Villanueva, J	1
Crofoot, G	1
Custodio, JM	1
Plummer, A	1
Zhong, L	1
Cao, H	1
Martin, H	1
Callebaut, C	1
Cheng, AK	1
Fordyce, MW	1
McCallister, S	1
Lopera, F	1
Ardilla, A	1
Martínez, A	1
Madrigal, L	1
Arango-Viana, JC	1
Lemere, CA	1
Arango-Lasprilla, JC	1
Hincapíe, L	1
Arcos-Burgos, M	1
Ossa, JE	1
Behrens, IM	1
Norton, J	1
Lendon, C	1
Goate, AM	1
Ruiz-Linares, A	1
Rosselli, M	1
Kosik, KS	1
Stanley, RJ	1
Melson, GL	1
Cubillo, E	1
Hesker, AE	1

Clinical Trials (4)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Trea[NCT01780506]	Phase 3	872 participants (Actual)	Interventional	2012-12-26	Completed
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treat[NCT01797445]	Phase 3	872 participants (Actual)	Interventional	2013-03-12	Completed
Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (Genvoya) as Maintenance Treatment of HIV-1/Hepatitis B Virus (HBV)-Coinfected Patients: an Observational Study[NCT03425994]		275 participants (Actual)	Observational [Patient Registry]	2018-02-06	Active, not recruiting
Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE) - A Phase II Exploratory Study[NCT04004702]	Phase 2	65 participants (Anticipated)	Interventional	2020-01-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change From Baseline in CD4+ Cell Count at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Intervention	cells/µL (Mean)
E/C/F/TAF	323
E/C/F/TDF	310

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Intervention	cells/µL (Mean)
E/C/F/TAF	235
E/C/F/TDF	221

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Intervention	cells/µL (Mean)
E/C/F/TAF	285
E/C/F/TDF	271

Change From Baseline in Serum Creatinine at Week 144

(NCT01780506)
Timeframe: Baseline; Week 144

Intervention	mg/dL (Mean)
E/C/F/TAF	0.04
E/C/F/TDF	0.08

Change From Baseline in Serum Creatinine at Week 48

(NCT01780506)
Timeframe: Baseline; Week 48

Intervention	mg/dL (Mean)
E/C/F/TAF	0.08
E/C/F/TDF	0.11

Change From Baseline in Serum Creatinine at Week 96

(NCT01780506)
Timeframe: Baseline; Week 96

Intervention	mg/dL (Mean)
E/C/F/TAF	0.05
E/C/F/TDF	0.07

Percent Change From Baseline in Hip BMD at Week 144

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Mean)
E/C/F/TAF	-0.826
E/C/F/TDF	-3.475

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-0.951
E/C/F/TDF	-3.515

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-0.865
E/C/F/TDF	-3.200

Percent Change From Baseline in Spine BMD at Week 144

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Mean)
E/C/F/TAF	-0.809
E/C/F/TDF	-3.023

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-1.337
E/C/F/TDF	-2.956

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-0.907
E/C/F/TDF	-3.053

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 144

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Median)
E/C/F/TAF	-24.6
E/C/F/TDF	60.4

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	-32.8
E/C/F/TDF	18.0

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	-33.5
E/C/F/TDF	32.5

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 144

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 144

Intervention	percent change (Median)
E/C/F/TAF	37.4
E/C/F/TDF	106.9

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	11.3
E/C/F/TDF	75.0

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01780506)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	6.9
E/C/F/TDF	51.2

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Week 48

Intervention	percentage of participants (Number)
E/C/F/TAF	93.1
E/C/F/TDF	92.8

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 144

Grades 1 (mild), 2 (moderate), and 3 (severe) were the highest treatment-emergent postbaseline grades for urine protein using the dipstick method. The worst postbaseline value is presented for each participant. (NCT01780506)
Timeframe: Up to 144 weeks

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	31.3	6.0	0.2
E/C/F/TDF	37.1	7.0	0.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 48

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	25.8	4.6	0
E/C/F/TDF	32.3	4.9	0.2

Percentage of Participants Experiencing Treatment-emergent Proteinuria Through Week 96

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	28.8	5.1	0.2
E/C/F/TDF	33.9	5.8	0.2

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48, 96, and 144

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48, 96, and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 48, 96. and 144

Intervention	percentage of participants (Number)
	Week 48	Week 96	Week 144
E/C/F/TAF	86.4	84.4	84.6
E/C/F/TDF	87.3	83.6	80.1

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 96 and 144

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Weeks 96 and 144 were analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01780506)
Timeframe: Weeks 96 and 144

Intervention	percentage of participants (Number)
	Week 96	Week 144
E/C/F/TAF	89.2	86.9
E/C/F/TDF	88.2	83.1

Change From Baseline in CD4+ Cell Count at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Intervention	cells/µL (Mean)
E/C/F/TAF	225
E/C/F/TDF	200

Change From Baseline in CD4+ Cell Count at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Intervention	cells/µL (Mean)
E/C/F/TAF	274
E/C/F/TDF	260

Change From Baseline in Serum Creatinine at Week 48

(NCT01797445)
Timeframe: Baseline; Week 48

Intervention	mg/dL (Mean)
E/C/F/TAF	0.08
E/C/F/TDF	0.12

Change From Baseline in Serum Creatinine at Week 96

(NCT01797445)
Timeframe: Baseline; Week 96

Intervention	mg/dL (Mean)
E/C/F/TAF	0.04
E/C/F/TDF	0.07

Percent Change From Baseline in Hip BMD at Week 96

Hip BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-0.364
E/C/F/TDF	-3.023

Percent Change From Baseline in Hip Bone Mineral Density (BMD) at Week 48

Hip BMD was assessed by dual energy x-ray absorptiometry (DXA) scan. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-0.420
E/C/F/TDF	-2.603

Percent Change From Baseline in Spine BMD at Week 48

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Mean)
E/C/F/TAF	-1.278
E/C/F/TDF	-2.759

Percent Change From Baseline in Spine BMD at Week 96

Spine BMD was assessed by DXA scan. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Mean)
E/C/F/TAF	-1.017
E/C/F/TDF	-2.516

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 48

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	-29.3
E/C/F/TDF	32.3

Percent Change From Baseline in Urine Beta-2-microglobulin to Creatinine Ratio at Week 96

Urine Beta-2-microglobulin is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	-31.0
E/C/F/TDF	35.2

Percent Change From Baseline in Urine RBP to Creatinine Ratio at Week 96

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 96

Intervention	percent change (Median)
E/C/F/TAF	16.9
E/C/F/TDF	73.7

Percent Change From Baseline in Urine Retinol Binding Protein (RBP) to Creatinine Ratio at Week 48

Urine RBP is a renal biomarker which is used to detect drug-induced kidney injury. (NCT01797445)
Timeframe: Baseline; Week 48

Intervention	percent change (Median)
E/C/F/TAF	13.3
E/C/F/TDF	51.7

Percentage of Participants Achieving HIV-1 RNA < 50 Copies/mL at Week 48

Intervention	percentage of participants (Number)
E/C/F/TAF	91.6
E/C/F/TDF	88.5

Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 96

The percentage of participants achieving HIV-1 RNA < 50 copies/mL at Week 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Week 96

Intervention	percentage of participants (Number)
E/C/F/TAF	84.0
E/C/F/TDF	82.3

Percentage of Participants With HIV-1 RNA < 20 Copies/mL at Weeks 48 and 96

The percentage of participants achieving HIV-1 RNA < 20 copies/mL at Weeks 48 and 96 was analyzed using the snapshot algorithm, which defines a patient's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. (NCT01797445)
Timeframe: Weeks 48 and 96

Intervention	percentage of participants (Number)
	Week 48	Week 96
E/C/F/TAF	82.4	78.7
E/C/F/TDF	80.7	76.8

Percentage of Participants With Treatment-emergent Proteinuria Through Week 48

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	27.3	4.7	0
E/C/F/TDF	31.6	4.6	0

Percentage of Participants With Treatment-emergent Proteinuria Through Week 96

Intervention	percentage of participants (Number)
	Grade 1	Grade 2	Grade 3
E/C/F/TAF	31.8	5.4	0
E/C/F/TDF	36.9	5.1	0

Trials

2 trials available for alanine and Bilateral Headache

Article	Year
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet (London, England), 2015, Jun-27, Volume: 385, Issue:9987 Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Arthralgia; Bone Density; Carbamates; CD4 Lymphocyte Count	2015
A comparison of three cholecystographic agents. A double-blind study with and without a prior fatty meal. Radiology, 1974, Volume: 112, Issue:3 Topics: Alanine; Butyrates; Cholecystography; Clinical Trials as Topic; Contrast Media; Diarrhea; Dietary Fa	1974

Other Studies

1 other study available for alanine and Bilateral Headache

Article	Year
Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA, 1997, Mar-12, Volume: 277, Issue:10 Topics: Adult; Age of Onset; Alanine; Alzheimer Disease; Autopsy; Brain; Codon; Female; Glutamic Acid; Heada	1997